Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.10.19	Karolinska Development’s portfolio company OssDsign receives US FDA clearance for Cranial PSI Accessories (GlobeNewswire)
08.10.19	Karolinska Development’s portfolio company Aprea Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire)
03.10.19	Karolinska Development’s portfolio company Aprea Therapeutics has priced its initial public offering (GlobeNewswire)
27.09.19	Karolinska Development publishes prospectus supplement relating to the directed share issue to the Company’s convertible holders (GlobeNewswire)
27.09.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
23.09.19	Karolinska Developments portfolio company Lipidor has been approved for listing on Nasdaq First North Growth Market (GlobeNewswire)
23.09.19	Karolinska Development’s portfolio company Aprea Therapeutics sets price range for potential initial public offering (GlobeNewswire)
12.09.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
09.09.19	Karolinska Development's portfolio company Aprea Therapeutics has filed a registration statement relating to its shares of common stock with the U.S. Securities and Exchange Commission (GlobeNewswire)
30.08.19	Interim Report January - June 2019 (GlobeNewswire)
29.08.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
28.08.19	Karolinska Development's portfolio company Promimic receives FDA approval for its HAnano Surface® on a spinal implant (GlobeNewswire)
20.08.19	Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219 (GlobeNewswire)
16.08.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
16.08.19	New date for publication of Karolinska Developments Interim Report January – June 2019 (GlobeNewswire)
09.08.19	arolinska Development's portfolio company OssDsign prepares for launch in Japan following regulatory filing (GlobeNewswire)
05.08.19	Karolinska Development's portfolio company Aprea Therapeutics appoints Scott Coiante as CFO (GlobeNewswire)
02.08.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
19.07.19	Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma (GlobeNewswire)
19.07.19	Karolinska Development extends the subscription period in the directed share issue to holders of the Company’s convertible loan (GlobeNewswire)
09.07.19	Karolinska Development’s portfolio company Dilafor initiates Phase 2b clinical trial with tafoxiparin in women planned for labor induction (GlobeNewswire)
05.07.19	Karolinska Development publishes prospectus relating to the directed share issue (GlobeNewswire)
01.07.19	Karolinska Development appoints Fredrik Järrsten as Deputy CEO (GlobeNewswire)
28.06.19	Karolinska Development´s Annual General Meeting 2019 (GlobeNewswire)
28.06.19	Update concerning subscription undertakings in Karolinska Development’s directed share issue to the holders of the Company’s convertible loan (GlobeNewswire)
27.06.19	Karolinska Development sells its ownership in Pharmanest for SEK 23 million (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten